Astec LifeSciences Limited (ASTEC) - Total Assets
Based on the latest financial reports, Astec LifeSciences Limited (ASTEC) holds total assets worth Rs8.83 Billion INR (≈ $95.53 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net assets of Astec LifeSciences Limited for net asset value and shareholders' equity analysis.
Astec LifeSciences Limited - Total Assets Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's total assets have evolved over time, based on quarterly financial data.
Astec LifeSciences Limited - Asset Composition Analysis
Current Asset Composition (March 2025)
Astec LifeSciences Limited's total assets of Rs8.83 Billion consist of 38.7% current assets and 61.3% non-current assets.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 0.1% |
| Accounts Receivable | Rs1.47 Billion | 16.7% |
| Inventory | Rs1.60 Billion | 18.1% |
| Property, Plant & Equipment | Rs4.97 Billion | 56.4% |
| Intangible Assets | Rs234.49 Million | 2.7% |
| Goodwill | Rs0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Astec LifeSciences Limited's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ASTEC company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Astec LifeSciences Limited's current assets represent 38.7% of total assets in 2025, a decrease from 56.1% in 2008.
- Cash Position: Cash and equivalents constituted 0.1% of total assets in 2025, down from 2.0% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is property, plant & equipment at 56.4% of total assets.
Astec LifeSciences Limited Competitors by Total Assets
Key competitors of Astec LifeSciences Limited based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Yangnong Chemical Co Ltd
SHG:600486
|
China | CN¥18.24 Billion |
|
Chengdu Wintrue Holding Co Ltd
SHE:002539
|
China | CN¥25.55 Billion |
|
Hubei Yihua Chemical Industry Co Ltd
SHE:000422
|
China | CN¥45.04 Billion |
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SHG:605033
|
China | CN¥1.91 Billion |
|
Fanli Digital Technology Co Ltd
SHG:600228
|
China | CN¥575.15 Million |
|
Insumos Agroquimicos SA
BA:INAG
|
Argentina | AR$45.35 Billion |
|
Cho Bi
KO:001550
|
Korea | ₩121.71 Billion |
|
Amoeba SA
PA:ALMIB
|
France | €6.37 Million |
Astec LifeSciences Limited - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.04 | 0.81 | 1.00 |
| Quick Ratio | 0.54 | 0.41 | 0.59 |
| Cash Ratio | 0.00 | 0.01 | 0.00 |
| Working Capital | Rs138.55 Million | Rs-693.53 Million | Rs-7.00 Million |
Astec LifeSciences Limited - Advanced Valuation Insights
This section examines the relationship between Astec LifeSciences Limited's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.46 |
| Latest Market Cap to Assets Ratio | 0.02 |
| Asset Growth Rate (YoY) | -9.6% |
| Total Assets | Rs8.81 Billion |
| Market Capitalization | $167.40 Million USD |
Valuation Analysis
Below Book Valuation: The market values Astec LifeSciences Limited's assets below their book value (0.02x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Astec LifeSciences Limited's assets decreased by 9.6% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Astec LifeSciences Limited (2008–2025)
The table below shows the annual total assets of Astec LifeSciences Limited from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-03-31 | Rs8.81 Billion ≈ $95.32 Million |
-9.59% |
| 2024-03-31 | Rs9.75 Billion ≈ $105.43 Million |
-0.46% |
| 2023-03-31 | Rs9.79 Billion ≈ $105.92 Million |
+9.22% |
| 2022-03-31 | Rs8.97 Billion ≈ $96.98 Million |
+32.35% |
| 2021-03-31 | Rs6.78 Billion ≈ $73.28 Million |
+18.52% |
| 2020-03-31 | Rs5.72 Billion ≈ $61.83 Million |
+23.99% |
| 2019-03-31 | Rs4.61 Billion ≈ $49.86 Million |
+11.59% |
| 2018-03-31 | Rs4.13 Billion ≈ $44.68 Million |
+23.86% |
| 2017-03-31 | Rs3.34 Billion ≈ $36.08 Million |
-10.18% |
| 2016-03-31 | Rs3.71 Billion ≈ $40.17 Million |
+2.29% |
| 2015-03-31 | Rs3.63 Billion ≈ $39.27 Million |
+27.43% |
| 2014-03-31 | Rs2.85 Billion ≈ $30.82 Million |
+9.14% |
| 2013-03-31 | Rs2.61 Billion ≈ $28.23 Million |
+12.81% |
| 2012-03-31 | Rs2.31 Billion ≈ $25.03 Million |
+29.17% |
| 2011-03-31 | Rs1.79 Billion ≈ $19.38 Million |
+16.55% |
| 2010-03-31 | Rs1.54 Billion ≈ $16.62 Million |
+57.46% |
| 2009-03-31 | Rs976.23 Million ≈ $10.56 Million |
+24.30% |
| 2008-03-31 | Rs785.37 Million ≈ $8.49 Million |
-- |
About Astec LifeSciences Limited
Astec LifeSciences Limited, together with its subsidiaries, manufactures and sells agrochemical active ingredients and pharmaceutical intermediates in India. The company provides triazole fungicides for use in field crops; foliar treatment for the control of scab, powdery mildew, shot-hole, blossom blight, and rust; seed treatment for the control of seed and soil-borne diseases in cotton and maiz… Read more